Findings of Research Misconduct, 56076-56077 [2014-22192]
Download as PDF
<![CDATA[
asabaliauskas on DSK5VPTVN1PROD with NOTICES
56076
Federal Register / Vol. 79, No. 181 / Thursday, September 18, 2014 / Notices
glucosamine 3–O-sulfotransferase 2
genes as a biomarker in colorectal
cancer.’’ Anticancer Res. 30(12):4811–
8, 2010 Dec (hereafter referred to as
‘‘AR 2010’’); Retraction in: Anticancer
Res. 32(11):5138, 2012 Nov.
Respondent falsified data representing
glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) loading
controls and methylated/unmethylated
polymerase chain reaction (PCR) in
reverse transcription-PCR (RT–PCR) gel
panels.
Specifically, ORI found by a
preponderance of the evidence that
Respondent engaged in research
misconduct by knowingly,
intentionally, and recklessly falsely
reporting the results of RT–PCR
experiments by:
1. Reusing and relabeling an image
and claiming it represents different
experiments of human tumor cell lines
subjected to different treatments;
specifically, an identical image was
used to represent the:
(a) GAPDH RT–PCR panels of several
lymphoma, leukemia, multiple
myeloma, and colorectal cancer cell
lines in CCR 2004, Figures 1A and 1B,
IJC 2005, Figure 1A, IJC 2006, Figures
1A and 2A, and AR 2010, Figure 1A
(b) GAPDH RT–PCR panels of the
lymphoma cell lines BC–1 and Raji in
CCR 2004, Figure 1B, lanes 1–3, and the
colorectal cancer cell lines HCT116 and
COLO201 in AR 2010, Figure 1C, lanes
4–6
(c) unmethylated form of p16
(p16UM) controls in the methylationspecific PCR (MSP) panels for the
leukemia (Le) and multiple myeloma
(MM) samples in CCR 2004, Figure 2
(d) p16UM MSP panels for the
lymphoma (Ly) and Le samples in CCR
2004, Figure 2, and the unmethylated
(UM) bands MSP panel for the
colorectal cancer (CRC) cell line in IJC
2005, Figure 5.
2. Manipulating an image and
claiming it represents a gel with
contiguous lanes; specifically, the RT–
PCR products in the lanes of gels were
cropped, spliced, and pasted together to
form a single image for the MSP panels
in IJC 2006, Figure 3.
Dr. Takahashi has entered into a
Voluntary Settlement Agreement
(Agreement) and has voluntarily agreed
for a period of three (3) years, beginning
on August 26, 2014:
(1) To have his research supervised;
Respondent agrees that prior to the
submission of an application for U.S.
Public Health Service (PHS) support for
a research project on which the
Respondent’s participation is proposed
and prior to Respondent’s participation
VerDate Sep<11>2014
17:27 Sep 17, 2014
Jkt 232001
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of Respondent’s
duties is submitted to ORI for approval;
the supervision plan must be designed
to ensure the scientific integrity of
Respondent’s research; Respondent
agrees that he shall not participate in
any PHS-supported research until such
a supervision plan is submitted to and
approved by ORI; Respondent agrees to
maintain responsibility for compliance
with the agreed upon supervision plan;
(2) that any institution employing him
shall submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract; and
(3) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant.
FOR FURTHER INFORMATION CONTACT:
Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453–
8200.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014–22191 Filed 9–17–14; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Makoto Suzuki, M.D., University of
Texas Southwestern Medical Center:
Based on the report of an investigation
conducted by the University of Texas
Southwestern Medical Center (UT
Southwestern) and analysis conducted
by ORI in its oversight review, ORI
found that Dr. Makoto Suzuki, currently
a Professor in the Department of
Thoracic Surgery, Kumamoto University
Hospital, Kumamoto, Japan, and
formerly a Visiting Scientist in the
SUMMARY:
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
Hamon Center for Therapeutic Oncology
Research, UT Southwestern, engaged in
research misconduct in research
supported by National Cancer Institute
(NCI), National Institutes of Health
(NIH), grants P50 CA070907 and U01
CA084971.
ORI found that Respondent
knowingly, intentionally, and recklessly
falsified data reported in six (6)
publications:
• Suzuki, M., Hao, C., Takahashi, T.,
Shigematsu, H., Shivapurkar, N.,
Sathyanarayana, U.G., Iizasa, T.,
Fujisawa, T., Hiroshima, K., & Gazdar,
A.F. ‘‘Aberrant methylation of SPARC
in human lung cancers.’’ Br J Cancer
92(5):942–8, 2005 Mar 14 (hereafter
referred to as ‘‘BJC 2005–1’’);
Retraction in: Br J Cancer 108(3):744,
2013 Feb 19
• Suzuki, M., Shigematsu, H., Shames,
D.S., Sunaga, N., Takahashi, T.,
Shivapurkar, N., Iizasa, T., Frankel,
E.P., Minna, J.D., Fujisawa, T., &
Gazdar, A.F. ‘‘DNA methylation
associated inactivation of TGFbetarelated genes DRM/Gremlin, RUNX3,
and HPP1 in human cancers.’’ Br J
Cancer 93(9):1029–37, 2005 Oct 31
(hereafter referred to as ‘‘BJC 2005–
2’’); Retraction in: Br J Cancer
109(12)3132, 2013 Dec 10
• Suzuki, M., Shigematsu, H.,
Takahashi, T., Shivapurkar, N.,
Sathyanarayana, U.G., Iizasa, T.,
Fujisawa, T., & Gazdar, A.F.
‘‘Aberrant methylation of Reprimo in
lung cancer.’’ Lung Cancer 47(3):309–
14; 2005 Mar (hereafter referred to as
‘‘LC 2005’’); Retraction in: Lung
Cancer 85(2):337, 2014 August
• Suzuki, M., Toyooka, S., Shivapurkar,
N., Shigematsu, H., Miyajima, K.,
Takahashi, T., Stastny, V., Zern, A.L.,
Fujisawa, T., Pass, H.I., Carbone, M.,
& Gazdar, A.F. ‘‘Aberrant methylation
profile of human malignant
mesotheliomas and its relationship to
SV40 infection.’’ Oncogene
24(7):1302–8, 2005 Feb 10 (hereafter
referred to as ‘‘ONC 2005’’);
Retraction in: Oncogene 33(21):2814,
2014 May 22
• Suzuki, M., Shigematsu, H.,
Shivapurkar, N., Reddy, J., Miyajima,
K., Takahashi, T., Gazdar, A.F., &
Frenkel, E.P. ‘‘Methylation of
apoptosis related genes in the
pathogenesis and prognosis of
prostate cancer.’’ Cancer Lett.
242(2):222–30, 2006 Oct 28 (hereafter
referred to as ‘‘CL 2006’’)
• Suzuki, M., Shigematsu, H., Shames,
D.S., Sunaga, N., Takahashi, T.,
Shivapurkar, N., Iizasa, T., Minna,
J.D., Fujisawa, T., & Gazdar, A.F.
‘‘Methylation and gene silencing of
E:\FR\FM\18SEN1.SGM
18SEN1
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 181 / Thursday, September 18, 2014 / Notices
the Ras-related GTPase gene in lung
and breast cancers.’’ Ann Surg Oncol.
14(4):1397–404, 2007 Apr (hereafter
referred to as ‘‘ASO 2007’’).
Respondent falsified data representing
glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) loading
controls and methylated/unmethylated
polymerase chain reaction (PCR) in
reverse transcription-PCR (RT–PCR) gel
panels.
Specifically, ORI found by a
preponderance of the evidence that
Respondent engaged in research
misconduct by knowingly,
intentionally, and recklessly falsely
reporting the results of RT–PCR
experiments by:
1. Reusing and relabeling an image
and claiming it represents different
experiments of human tumor cell lines
subjected to different treatments;
specifically, an identical image was
used to represent the:
(a) GAPDH RT–PCR panels in BJC
2005–01, Figure 1A, lanes 4–12, and
Figure 1C, lanes 4–12
(b) GAPDH RT–PCR panels in BJC
2005–2, Figures 1A and 1B, and ASO
2007, Figures 1A and 1B
(c) unmethylated form of p16 (p16U)
RT–PCR panel in CL 2006, Figure 1,
lanes 3–10, positive (P) and negative (N)
controls, and the p16 U RT–PCR panel
in ONC 2005, Figure 2A.
2. Manipulating an image and
claiming it represents a gel with
contiguous lanes; specifically, the RT–
PCR products in the lanes of gels were
cropped, spliced, and pasted together to
form a single image for the:
(a) GAPDH RT–PCR panels in LC
2005, Figures 1A and 1B
(b) methylated form of Decoy receptor
2 (DcR2 M) methylation-specific PCR
(MSP) panel in CL 2006, Figure 1
(c) methylated form of small Rasrelated GTPase (RRAD M) MSP panel in
ASO 2007, Figure 3B.
Dr. Suzuki has entered into a
Voluntary Settlement Agreement
(Agreement) and has voluntarily agreed
for a period of three (3) years, beginning
on August 26, 2014:
(1) To have his research supervised;
Respondent agrees that prior to the
submission of an application for U.S.
Public Health Service (PHS) support for
a research project on which the
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of Respondent’s
duties is submitted to ORI for approval;
the supervision plan must be designed
to ensure the scientific integrity of
Respondent’s research; Respondent
VerDate Sep<11>2014
17:27 Sep 17, 2014
Jkt 232001
agrees that he shall not participate in
any PHS-supported research until such
a supervision plan is submitted to and
approved by ORI; Respondent agrees to
maintain responsibility for compliance
with the agreed upon supervision plan;
(2) that any institution employing him
shall submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract; and
(3) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant.
FOR FURTHER INFORMATION CONTACT:
Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453–
8200.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014–22192 Filed 9–17–14; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Multi-Agency Informational Meeting
Concerning Compliance With the
Federal Select Agent Program; Public
Webcast
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of public Webcast.
AGENCY:
The HHS Centers for Disease
Control and Prevention’s Division of
Select Agents and Toxins (DSAT) and
the USDA Animal and Plant Health
Inspection Service (APHIS), Agriculture
Select Agent Services (AgSAS) are
jointly charged with the oversight of the
possession, use and transfer of
biological agents and toxins that have
the potential to pose a severe threat to
public, animal or plant health or to
animal or plant products (select agents
and toxins). This joint effort constitutes
the Federal Select Agent Program. The
purpose of the Webcast is to provide
guidance related to the Federal Select
SUMMARY:
PO 00000
Frm 00029
Fmt 4703
Sfmt 9990
56077
Agent Program for interested
individuals.
The Webcast will be held on
Friday, November 14, 2014 from 10 a.m.
to 4 p.m. EST. All who wish to join the
Webcast must register by October 24,
2014. Registration instructions can be
found on the Web site https://
www.selectagents.gov.
DATES:
The Webcast will be
broadcast from the Centers for Disease
Control and Prevention’s facility, 1600
Clifton Road, Atlanta, GA 30333. This
will only be produced as a Webcast,
therefore no accommodations will be
provided for in-person participation.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
CDC: Ms. Diane Martin, Division of
Select Agents and Toxins, Office of
Public Health Preparedness and
Response, CDC, 1600 Clifton Road MS
A–46, Atlanta, GA 30333; phone:
404–718–2000; email: lrsat@cdc.gov.
APHIS: Dr. Keith Wiggins, APHIS
Agriculture Select Agent Services,
4700 River Road, Unit 2, Riverdale,
MD 20737; phone: 301–851–3300
(option 3); email: AgSAS@
aphis.usda.gov.
The
public Webcast is an opportunity for the
affected community (i.e., registered
entity responsible officials, alternate
responsible officials, and entity owners)
and other interested individuals to
obtain specific regulatory guidance and
information concerning biosafety,
security and incident response issues
related to the Federal Select Agent
Program.
Representatives from the Federal
Select Agent Program will be present
during the Webcast to address questions
and concerns from the Web participants.
Individuals who want to participate
in the Webcast must complete their
registration online by October 24, 2014.
The registration instructions are located
on this Web site: https://
www.selectagents.gov.
SUPPLEMENTARY INFORMATION:
Dated: September 15, 2014.
Ron A. Otten,
Acting Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
[FR Doc. 2014–22253 Filed 9–17–14; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\18SEN1.SGM
18SEN1
]]>Agencies
[Federal Register Volume 79, Number 181 (Thursday, September 18, 2014)]
[Notices]
[Pages 56076-56077]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-22192]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Makoto Suzuki, M.D., University of Texas Southwestern Medical
Center: Based on the report of an investigation conducted by the
University of Texas Southwestern Medical Center (UT Southwestern) and
analysis conducted by ORI in its oversight review, ORI found that Dr.
Makoto Suzuki, currently a Professor in the Department of Thoracic
Surgery, Kumamoto University Hospital, Kumamoto, Japan, and formerly a
Visiting Scientist in the Hamon Center for Therapeutic Oncology
Research, UT Southwestern, engaged in research misconduct in research
supported by National Cancer Institute (NCI), National Institutes of
Health (NIH), grants P50 CA070907 and U01 CA084971.
ORI found that Respondent knowingly, intentionally, and recklessly
falsified data reported in six (6) publications:
Suzuki, M., Hao, C., Takahashi, T., Shigematsu, H.,
Shivapurkar, N., Sathyanarayana, U.G., Iizasa, T., Fujisawa, T.,
Hiroshima, K., & Gazdar, A.F. ``Aberrant methylation of SPARC in human
lung cancers.'' Br J Cancer 92(5):942-8, 2005 Mar 14 (hereafter
referred to as ``BJC 2005-1''); Retraction in: Br J Cancer 108(3):744,
2013 Feb 19
Suzuki, M., Shigematsu, H., Shames, D.S., Sunaga, N.,
Takahashi, T., Shivapurkar, N., Iizasa, T., Frankel, E.P., Minna, J.D.,
Fujisawa, T., & Gazdar, A.F. ``DNA methylation associated inactivation
of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human
cancers.'' Br J Cancer 93(9):1029-37, 2005 Oct 31 (hereafter referred
to as ``BJC 2005-2''); Retraction in: Br J Cancer 109(12)3132, 2013 Dec
10
Suzuki, M., Shigematsu, H., Takahashi, T., Shivapurkar, N.,
Sathyanarayana, U.G., Iizasa, T., Fujisawa, T., & Gazdar, A.F.
``Aberrant methylation of Reprimo in lung cancer.'' Lung Cancer
47(3):309-14; 2005 Mar (hereafter referred to as ``LC 2005'');
Retraction in: Lung Cancer 85(2):337, 2014 August
Suzuki, M., Toyooka, S., Shivapurkar, N., Shigematsu, H.,
Miyajima, K., Takahashi, T., Stastny, V., Zern, A.L., Fujisawa, T.,
Pass, H.I., Carbone, M., & Gazdar, A.F. ``Aberrant methylation profile
of human malignant mesotheliomas and its relationship to SV40
infection.'' Oncogene 24(7):1302-8, 2005 Feb 10 (hereafter referred to
as ``ONC 2005''); Retraction in: Oncogene 33(21):2814, 2014 May 22
Suzuki, M., Shigematsu, H., Shivapurkar, N., Reddy, J.,
Miyajima, K., Takahashi, T., Gazdar, A.F., & Frenkel, E.P.
``Methylation of apoptosis related genes in the pathogenesis and
prognosis of prostate cancer.'' Cancer Lett. 242(2):222-30, 2006 Oct 28
(hereafter referred to as ``CL 2006'')
Suzuki, M., Shigematsu, H., Shames, D.S., Sunaga, N.,
Takahashi, T., Shivapurkar, N., Iizasa, T., Minna, J.D., Fujisawa, T.,
& Gazdar, A.F. ``Methylation and gene silencing of
[[Page 56077]]
the Ras-related GTPase gene in lung and breast cancers.'' Ann Surg
Oncol. 14(4):1397-404, 2007 Apr (hereafter referred to as ``ASO
2007'').
Respondent falsified data representing glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) loading controls and methylated/unmethylated
polymerase chain reaction (PCR) in reverse transcription-PCR (RT-PCR)
gel panels.
Specifically, ORI found by a preponderance of the evidence that
Respondent engaged in research misconduct by knowingly, intentionally,
and recklessly falsely reporting the results of RT-PCR experiments by:
1. Reusing and relabeling an image and claiming it represents
different experiments of human tumor cell lines subjected to different
treatments; specifically, an identical image was used to represent the:
(a) GAPDH RT-PCR panels in BJC 2005-01, Figure 1A, lanes 4-12, and
Figure 1C, lanes 4-12
(b) GAPDH RT-PCR panels in BJC 2005-2, Figures 1A and 1B, and ASO
2007, Figures 1A and 1B
(c) unmethylated form of p16 (p16U) RT-PCR panel in CL 2006, Figure
1, lanes 3-10, positive (P) and negative (N) controls, and the p16 U
RT-PCR panel in ONC 2005, Figure 2A.
2. Manipulating an image and claiming it represents a gel with
contiguous lanes; specifically, the RT-PCR products in the lanes of
gels were cropped, spliced, and pasted together to form a single image
for the:
(a) GAPDH RT-PCR panels in LC 2005, Figures 1A and 1B
(b) methylated form of Decoy receptor 2 (DcR2 M) methylation-
specific PCR (MSP) panel in CL 2006, Figure 1
(c) methylated form of small Ras-related GTPase (RRAD M) MSP panel
in ASO 2007, Figure 3B.
Dr. Suzuki has entered into a Voluntary Settlement Agreement
(Agreement) and has voluntarily agreed for a period of three (3) years,
beginning on August 26, 2014:
(1) To have his research supervised; Respondent agrees that prior
to the submission of an application for U.S. Public Health Service
(PHS) support for a research project on which the Respondent's
participation is proposed and prior to Respondent's participation in
any capacity on PHS-supported research, Respondent shall ensure that a
plan for supervision of Respondent's duties is submitted to ORI for
approval; the supervision plan must be designed to ensure the
scientific integrity of Respondent's research; Respondent agrees that
he shall not participate in any PHS-supported research until such a
supervision plan is submitted to and approved by ORI; Respondent agrees
to maintain responsibility for compliance with the agreed upon
supervision plan;
(2) that any institution employing him shall submit, in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived and that the
data, procedures, and methodology are accurately reported in the
application, report, manuscript, or abstract; and
(3) to exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8200.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014-22192 Filed 9-17-14; 8:45 am]
BILLING CODE 4150-28-P
